However, due to its low sensitivity (18%), CEA cannot be used as a screening method for malignant IPMNs, while it can be used to rule-in IPMN malignancy because of its high specificity (95%) [34]. The gene discussed is CEACAM5; the disease is pancreatic intraductal papillary-mucinous neoplasm.